secwatch.observer — SEC 8-K summary
======================================

Issuer:     Definium Therapeutics, Inc. (DFTX)
CIK:        0001813814
Form:       8-K
Filed at:   2026-04-22T23:59:59+00:00
Accession:  0001193125-26-170509
Event type: other_material
Sentiment:  positive
Materiality: 0.60
Item codes: 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Definium provides DT120 ODT clinical updates; MDD/GAD readouts in 2H 2026, expansion into PTSD
--------------------------------------------------------------------------------

- MDD Emerge trial topline data on track for late 2Q 2026; 149 participants randomized 1:1 to DT120 100 µg or placebo.
- GAD Voyage trial fully enrolled at 214 participants; topline data expected early 3Q 2026.
- GAD Panorama sample size re-estimated to 200; screening closed, topline readout now late 3Q 2026 (previously 2H 2026).
- PTSD program expanded with Phase 3 Haven study (~200 pts) initiating in 2027; primary endpoint CAPS-5 at Week 8.
- Company presented commercial strategy for DT120 ODT as a potential multi-billion-dollar opportunity.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1813814/000119312526170509/0001193125-26-170509-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1813814/000119312526170509/dftx-20260422.htm
  HTML page:      https://secwatch.observer/filing/0001193125-26-170509

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer